Production (Stage)
Amneal Pharmaceuticals, Inc.
AMRX
$7.16
-$0.03-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.83B | 2.79B | 2.68B | 2.60B | 2.50B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.83B | 2.79B | 2.68B | 2.60B | 2.50B |
| Cost of Revenue | 1.80B | 1.78B | 1.70B | 1.65B | 1.58B |
| Gross Profit | 1.03B | 1.02B | 979.05M | 943.11M | 913.40M |
| SG&A Expenses | 482.13M | 476.44M | 456.75M | 451.07M | 440.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.12M | 100.00K | 100.00K | 173.00K | 186.00K |
| Total Operating Expenses | 2.47B | 2.45B | 2.34B | 2.27B | 2.19B |
| Operating Income | 364.10M | 348.26M | 339.67M | 329.06M | 308.49M |
| Income Before Tax | 58.00M | -55.01M | -123.16M | -115.62M | -106.37M |
| Income Tax Expenses | 25.58M | 18.86M | 23.32M | 17.58M | 13.94M |
| Earnings from Continuing Operations | 32.42 | -73.88 | -146.48 | -133.20 | -120.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -45.47M | -43.01M | -37.98M | -41.41M | -48.39M |
| Net Income | -13.05M | -116.89M | -184.45M | -174.62M | -168.69M |
| EBIT | 364.10M | 348.26M | 339.67M | 329.06M | 308.49M |
| EBITDA | 604.92M | 584.45M | 566.66M | 554.29M | 535.26M |
| EPS Basic | -0.04 | -0.38 | -0.68 | -0.62 | -0.56 |
| Normalized Basic EPS | -0.05 | -0.07 | 0.01 | 0.02 | 0.01 |
| EPS Diluted | -0.04 | -0.38 | -0.69 | -0.63 | -0.57 |
| Normalized Diluted EPS | -0.05 | -0.07 | 0.01 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 1.24B | 1.24B | 1.17B | 1.01B | 858.95M |
| Average Diluted Shares Outstanding | 1.26B | 1.25B | 1.18B | 1.03B | 865.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |